---
document_datetime: 2025-11-14 11:25:53
document_pages: 3
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/plegridy-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: plegridy-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 1.691287
conversion_datetime: 2025-12-25 07:28:47.848898
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Plegridy

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                                        | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                        |
|----------------------|----------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|------------------------------------------------|
| Variation type IB /  | C.I.11 Introduction of, or change(s) to, the | 14/11/2025                          | N/A                                         |                                  | To update the RMP by updating the study status |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000307743                     | obligations and conditions of a marketing authorisation, including the risk management plan - C.I.11.z Change in due date for category 1, 2 or 3 studies in the RMP and/or Annex II - Accepted C.I.11.z (Type IB) - To update the RMP by updating the study status and milestones for study 105MS404, drug utilization in pregnancy exposure in second and third trimester of pregnancy, in line with the agreed protocol Version 3.0, submitted within procedure EMA/PAM0000263236. In addition, the MAH took the opportunity to (1) Update the QPPV details, (2) Remove post authorisation exposure data by country (per guidance on anonymisation of personal data, reference EMA/63692/2025, revision 3), (3) Update post authorisation exposure estimates based on the new data lock point, (4) Update clinical trial exposure based on the new data lock point, and (5) Template changes: Include a row for Section VII in the Summary of Significant Changes,   |            |          | and milestones for study 105MS404, drug utilization in pregnancy exposure in second and third trimester of pregnancy, in line with the agreed protocol Version 3.0, submitted within procedure EMA/PAM0000263236.   |
|---------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Variation type IA / EMA/VR/0000300515 | A. ADMINISTRATIVE CHANGES - A.4 Change in the name and/or address of: a manufacturer (including where relevant quality control testing sites); or an ASMF holder; or a supplier of the active substance, starting material, reagent or intermediate                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 16/10/2025 | Annex II |                                                                                                                                                                                                                     |

<div style=\"page-break-after: always\"></div>

|                                       | used in the manufacture of the active substance (where specified in the technical dossier) where no Ph. Eur. Certificate of Suitability is part of the approved dossier; or a manufacturer of a novel excipient (where specified in the technical dossier) - Accepted                                                                                                                                                                                                                                           |            |     |
|---------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| Variation type IA / EMA/VR/0000300753 | B.II.b.5 Change to in-process tests or limits applied during the manufacture of the finished product - B.II.b.5.c Deletion of a non-significant in-process test - Accepted                                                                                                                                                                                                                                                                                                                                      | 24/09/2025 | N/A |
| Variation type IB / EMA/VR/0000263823 | B.I.a.1 Change in the manufacturer of a starting material/reagent/intermediate used in the manufacturing process of the active substance or change in the manufacturer (including where relevant quality control testing sites) of the active substance, where no Ph. Eur. Certificate of Suitability is part of the approved dossier - B.I.a.1.f Changes to quality control testing arrangements for the active substance-replacement or addition of a site where batch control/testing takes place - Accepted | 13/05/2025 | N/A |